

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Telix Pharmaceuticals Limited
ABN	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Christian Behrenbruch
Date of last notice	3 February 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-
Date of change	18 May 2022

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>22,675,000 fully paid ordinary shares (Indirect interest)</p> <p>400,000 fully paid ordinary shares (Direct interest)</p> <p>200,000 share options with an exercise price of \$2.23 per option and an expiry date of 12 January 2024. Options vest on 13 January 2023. Options granted following shareholder approval at the AGM held 12 May 2020 (Direct interest) (TLXO006).</p> <p>100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021. (Direct interest) (TLXO009).</p>
<p>Class</p>	<p>Share Appreciation Rights (SARs)</p>
<p>Number acquired</p>	<p>139,672 Share Appreciation Rights</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>The consideration was non-cash – the SARs were issued to Dr Behrenbruch as part of his remuneration and following shareholder approval at the AGM held 18 May 2022. The Black Scholes valuation is \$2.4325 per SAR or \$339,752.14 in aggregate.</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>22,675,000 fully paid ordinary shares (Indirect interest)</p> <p>400,000 fully paid ordinary shares (Direct interest)</p> <p>200,000 share options with an exercise price of \$2.23 per option and an expiry date of 12 January 2024. Options vest on 13 January 2023. Options granted following shareholder approval at the AGM held 12 May 2020 (Direct interest) (TLXO006).</p> <p>100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021. (Direct interest) (TLXO009).</p> <p>139,672 Share Appreciation Rights (Direct interest) (TLXO014) issued following shareholder approval at the AGM held 18 May 2022.</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Allotment of 139,672 Share Appreciation Rights under the Telix Equity Incentive Plan.

Part 2 – Change of director's interests in contracts – NOT APPLICABLE

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.